OUR PRODUCTS
One platform. Multiple approaches
to precision cancer monitoring.
Altum Sequencing’s portfolio combines tumor profiling, MRD monitoring, clonal evolution analysis, and integrated data interpretation through liquid biopsy, ctDNA analysis, and ultra-sensitive NGS technologies.
Altum TRACKseq
Tumour-Informed MRD Monitoring
Track what matters - Ultra-sensitive patient-specific ctDNA monitoring using personalized mutation panels, enabling longitudinal detection of minimal residual disease and recurrence months before imaging.
Tumor-informed MRD approach: tracks up to 20 patient-specific somatic variants.
Ultra-deep sequencing
Longitudinal disease monitoring
Validated for hematologic and solid tumors
Up to 5.7 years earlier detection of recurrence vs CT Imaging
Key Clinical Applications
1
Treatment Response Monitoring
Quantitative ctDNA dynamics to distinguish responders from non-responders during and after therapy - supporting real-time treatment adaptation.
2
Early Relapse Detection
Detection of molecular recurrence before clinical or radiological progression in selected settings - enabling early intervention.
3
Long-Term Surveillance
Longitudinal ctDNA monitoring during remission and follow-up.
Altum DUALseq
Integrated MRD & Therapy Monitoring
Patient-specific NGS test to simultaneously monitor allogeneic and tumor cells , enabling simultaneous assessment of disease burden and therapy-related dynamics.
Combined MRD strategies: simultaneously deploys tumor-informed and tumor-naive approaches.
Single blood draw - single report - two analytical layers
Cell therapy kinetics assessment
Designed for advanced therapy settings
Key Clinical Applications
1
Cell Therapy Monitoring
Longitudinal monitoring of CAR-T and other cell-based therapies through ctDNA and therapy-related molecular signals.
2
Transplant & Chimerism Assessment
Tracking of transplant-derived markers alongside residual disease monitoring.
3
Comprehensive Disease Surveillance
Integrated monitoring of disease progression, molecular relapse, and therapeutic response.
Altum EVOseq
Clonal Evolution & Resistance Monitoring
No prior tumor tissue needed - a tumor-naïve ctDNA test designed to identify emerging resistance mutations and clonal evolution directly from liquid biopsy.
Tumour-naïve: no prior tissue biopsy required, works from blood.
Ideal for patients without available or adequate tissue for tumour profiling
Minipanels for SNVs & INDELs ultrasensititivy detection in relevant mutations
Key Clinical Applications
1
Resistance Mechanism Detection
Identification of emerging genomic alterations associated with therapy resistance.
2
Tumor Evolution Monitoring
Tracking of clonal dynamics throughout disease progression and treatment adaptation.
3
2nd Line Therapy Guidance
Support for therapy selection based on evolving molecular profiles.
Altum DxPanels
BASELINE genomic profiling
Comprehensive NGS panels designed for tumor characterization and biomarker identification across hematologic and solid tumors, supporting precision oncology decisions from diagnosis onward.
Comprehensive genomic profiling
Detects actionable mutations, SNVs, CNVs
Multi-cancer applicability
Supports both tissue and liquid biopsy input (depending on tumor type)
Compatible with clinical and research workflows
Key Clinical Applications
1
Diagnosis & Molecular Characterization
Identification of clinically relevant genomic alterations to support diagnosis and precision therapy selection.
2
Biomarker Selection for
MRD Monitoring
Selection of patient-specific variants for longitudinal ctDNA tracking through Altum TRACKseq.
3
Treatment Selection &
Clinical Research
Support for targeted therapy strategies, translational research, and molecular profiling programs.
Platform Comparison
Find the right test for
your clinical question
Each Altum Sequencing test is designed for a specific clinical context. Use this guide to identify which test is right for your patient or program.
